Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.51 |
| ▸ | PPARA | Q07869 | 4/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5937527 | 0.93 | PPARD (0.49) | PPARDPPARAPPARGMAPTPOLB | |
| SCHEMBL5187693 | 0.90 | PPARD (0.63) | PPARDPPARAPPARGMAPT | |
| SCHEMBL5386779 | 0.86 | PPARD (0.48) | PPARDPPARAPPARG | |
| SCHEMBL5937484 | 0.86 | PPARD (0.45) | PPARDPPARAPPARG | |
| SCHEMBL5187722 | 0.85 | PPARA (0.49) | PPARDPPARAPPARGMAPTPOLB | |
| SCHEMBL5188255 | 0.85 | PPARD (0.51) | PPARDPPARAPPARG | |
| SCHEMBL5188291 | 0.84 | PPARD (0.47) | PPARDPPARAPPARG | |
| SCHEMBL5188293 | 0.84 | PPARD (0.47) | PPARDPPARAPPARGMAPT | |
| SCHEMBL5187857 | 0.83 | PPARD (0.60) | PPARDPPARAPPARGMAPTPOLB | |
| SCHEMBL5186571 | 0.83 | PPARD (0.45) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863772-A1 | AMIDE DERIVATIVES AS PPAR ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007028424-A1 | AMIDE DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-20060183754-A1 | Amide bridged piphenyl or biazaphenyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183754-A1 | Amide bridged piphenyl or biazaphenyl derivatives | PPARD, PPARA, PPARG | PPARD 1/4885PPARA 2/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.